Key result
SCN1B variants occur in ~3% of SCN5A-negative Brugada syndrome patients.
Why the study?
The contribution of SCN1B gene variants to Brugada syndrome has been poorly investigated, especially in SCN5A-negative patients.
Cross-Sectional (n=145)
No
Answers are grounded in this paper and cite their sources.
SCN1B screening yields low in SCN5A-negative Brugada syndrome; leaves open variant contribution and need for larger validation studies.
Brugada syndrome is characterised by a typical ECG with ST segment elevation in the right precordial leads. Individuals with this condition are susceptible to ventricular arrhythmias and sudden cardiac death. The principal gene responsible for this syndrome is SCN5A, which encodes the α-subunit of the Nav1.5 voltage-gated sodium channel. Mutations involving other genes have been increasingly reported, but their contribution to Brugada syndrome has been poorly investigated. Here we focused on the SCN1B gene, which encodes the β1-subunit of the voltage-gated sodium channel and its soluble β1b isoform. SCN1B mutations have been associated with Brugada syndrome as well as with other cardiac arrhythmias and familial epilepsy. In this study, we have analysed SCN1B exons (including the alternatively-spliced exon 3A) and 3'UTR in 145 unrelated SCN5A-negative patients from a single centre. We took special care to report all identified variants (including polymorphisms), following the current nomenclature guidelines and considering both isoforms. We found two known and two novel (and likely deleterious) SCN1B variants. We also found two novel changes with low evidence of pathogenicity. Our findings contribute more evidence regarding the occurrence of SCN1B variants in Brugada syndrome, albeit with a low prevalence, which is in agreement with previous reports.
No takes yet. Share an insight, caveat, or question.
Ricci et al. (2014) conducted a cross-sectional in Brugada Syndrome (n=145). SCN1B gene variants was evaluated on Prevalence of likely pathogenic SCN1B variants. Genetic screening of 145 SCN5A-negative patients with Brugada syndrome identified four likely pathogenic SCN1B variants, indicating a low prevalence of 2.75%.
Synapse has enriched 10 related papers. Consider them for comparative context: